Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India.
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India.
Int J Pharm. 2023 Feb 5;632:122558. doi: 10.1016/j.ijpharm.2022.122558. Epub 2022 Dec 30.
Resveratrol (RVT) is a polyphenolic phytoestrogen which has shown antiproliferative activity in breast cancer. However, its low bioavailability and short half-life have restricted its use. The current study aimed to develop transdermal patches of RVT and evaluate its site-specific delivery for breast cancer therapy. Different penetration enhancers were screened using a computational tool, quantitative structure propery relationship (QSPR). The best permeation of RVT was observed in a patch comprising hydroxypropyl methylcellulose (HPMC) E15LV: HPMC-K4M: polyvinyl pyrrolidone (PVP) K30 in the ratio of 3:1:2 as release controlling polymers with Glycerol:Capryol 90 (4:1) as penetration enhancer and plasticizer. To assess the localized delivery of RVT, the patch was applied to the breast of female rats. Higher breast tissue disposition with lower systemic concentration was observed compared to oral administration, demonstrated by increased AUC and MRT. Further, the optimized RVT patches were tested in 7,12-Dimethylbenz[a]anthracene (DMBA) induced rat mammary cancer. Compared to oral RVT, the application of RVT tansdermal patches significantly reduced the tumor volume and serum CA 15-3, a cancer biomarker. Thus, the RVT transdermal patch may be a viable approach for ensuring high local concentration of drug for site-specific delivery in breast cancer therapy.
白藜芦醇(RVT)是一种多酚类植物雌激素,已显示出在乳腺癌中的抗增殖活性。然而,其生物利用度低和半衰期短限制了其应用。本研究旨在开发 RVT 的透皮贴剂,并评估其用于乳腺癌治疗的局部递药。使用计算工具定量构效关系(QSPR)筛选了不同的渗透增强剂。在由羟丙基甲基纤维素(HPMC)E15LV:HPMC-K4M:聚乙烯吡咯烷酮(PVP)K30 以 3:1:2 的比例作为释放控制聚合物,与甘油:辛酸癸酸(4:1)作为渗透增强剂和增塑剂组成的贴剂中观察到 RVT 的最佳渗透。为了评估 RVT 的局部递药,将贴剂应用于雌性大鼠的乳房。与口服给药相比,观察到更高的乳房组织处置和更低的系统浓度,表现为 AUC 和 MRT 增加。此外,还对优化的 RVT 贴剂进行了 7,12-二甲基苯并[a]蒽(DMBA)诱导的大鼠乳腺肿瘤的测试。与口服 RVT 相比,RVT 透皮贴片的应用显著降低了肿瘤体积和血清 CA 15-3,这是一种癌症生物标志物。因此,RVT 透皮贴剂可能是一种可行的方法,可确保药物在乳腺癌治疗中的局部高浓度和特定部位递药。